

# Michael S Stringer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4220825/publications.pdf>

Version: 2024-02-01

19  
papers

374  
citations

1162367

8  
h-index

887659

17  
g-index

25  
all docs

25  
docs citations

25  
times ranked

421  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Cilostazol and Isosorbide Mononitrate on Cerebral Hemodynamics in the LACI-1 Randomized Controlled Trial. <i>Stroke</i> , 2022, 53, 29-33.	1.0	10
2	Loss of the heterogeneous expression of flippase ATP11B leads to cerebral small vessel disease in a normotensive rat model. <i>Acta Neuropathologica</i> , 2022, 144, 283-303.	3.9	7
3	Prevalence and Significance of the Vessel-Cluster Sign on Susceptibility-Weighted Imaging in Patients With Severe Small Vessel Disease. <i>Neurology</i> , 2022, 99, .	1.5	11
4	Rationale and design of a longitudinal study of cerebral small vessel diseases, clinical and imaging outcomes in patients presenting with mild ischaemic stroke: Mild Stroke Study 3. <i>European Stroke Journal</i> , 2021, 6, 81-88.	2.7	17
5	A Review of Translational Magnetic Resonance Imaging in Human and Rodent Experimental Models of Small Vessel Disease. <i>Translational Stroke Research</i> , 2021, 12, 15-30.	2.3	18
6	Selective Motion Artefact Reduction via Radiomics and k-space Reconstruction for Improving Perivascular Space Quantification in Brain Magnetic Resonance Imaging. <i>Lecture Notes in Computer Science</i> , 2021, , 151-164.	1.0	1
7	Zooming in on cerebral small vessel function in small vessel diseases with 7T MRI: Rationale and design of the "ZOOM@SVDs" study. <i>Cerebral Circulation - Cognition and Behavior</i> , 2021, 2, 100013.	0.4	8
8	Cerebrovascular Reactivity Measurement Using Magnetic Resonance Imaging: A Systematic Review. <i>Frontiers in Physiology</i> , 2021, 12, 643468.	1.3	65
9	Sources of systematic error in DCE-MRI estimation of low-level blood-brain barrier leakage. <i>Magnetic Resonance in Medicine</i> , 2021, 86, 1888-1903.	1.9	21
10	A Comparison of CVR Magnitude and Delay Assessed at 1.5 and 3T in Patients With Cerebral Small Vessel Disease. <i>Frontiers in Physiology</i> , 2021, 12, 644837.	1.3	9
11	Relationship between inferior frontal sulcal hyperintensities on brain MRI, ageing and cerebral small vessel disease. <i>Neurobiology of Aging</i> , 2021, 106, 130-138.	1.5	5
12	Imaging neurovascular, endothelial and structural integrity in preparation to treat small vessel diseases. The INVESTIGATE-SVDs study protocol. Part of the SVDs@Target project. <i>Cerebral Circulation - Cognition and Behavior</i> , 2021, 2, 100020.	0.4	8
13	Sex Differences in Cerebral Small Vessel Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Neurology</i> , 2021, 12, 756887.	1.1	29
14	Tracer kinetic assessment of blood-brain barrier leakage and blood volume in cerebral small vessel disease: Associations with disease burden and vascular risk factors. <i>NeuroImage: Clinical</i> , 2021, 32, 102883.	1.4	7
15	Intracranial hemodynamic relationships in patients with cerebral small vessel disease. <i>Neurology</i> , 2020, 94, e2258-e2269.	1.5	86
16	Brain hyperintensities in magnetic resonance imaging of patients with mild acute focal neurology. <i>Neurological Sciences</i> , 2020, 41, 1633-1635.	0.9	0
17	A Framework for Jointly Assessing and Reducing Imaging Artefacts Automatically Using Texture Analysis and Total Variation Optimisation for Improving Perivascular Spaces Quantification in Brain Magnetic Resonance Imaging. <i>Communications in Computer and Information Science</i> , 2020, , 171-183.	0.4	4
18	Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial. <i>EClinicalMedicine</i> , 2019, 11, 34-43.	3.2	36

#	ARTICLE	IF	CITATIONS
19	Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability, safety and effect on intermediary endpoints of isosorbide mononitrate and cilostazol, separately and in combination. <i>International Journal of Stroke</i> , 2018, 13, 530-538.	2.9	22